Mesa Verde Venture Partners

Mesa Verde targets the earliest phases of company formation: seed-stage and start-up-stage life-science companies. The firm describes its mission as creating partnerships with entrepreneurs to build successful biomedical companies from inception.

The firm invests across pharmaceuticals, medical devices, diagnostics, life-science enabling tools, and digital health. Its disclosed exits confirm activity in dermatology, diagnostics, CNS therapeutics, genomics, and anti-infectives.

Mesa Verde deliberately concentrates on Southern California, the Southwest, and other regions it describes as traditionally underrepresented in life-science venture capital. This is a foundational element of its sourcing strategy, distinguishing it from firms centered on the Boston–San Francisco corridor.

The firm is led by three Managing Directors, supported by a group of advisors and partners with experience building and investing in early-stage life-science companies. Mesa Verde does not publicly name its Managing Directors on its website or LinkedIn as of the latest Altss review.

The firm relies on its San Diego location and deep regional ties to academic research institutions, university systems, and entrepreneurial networks in Southern California and the Southwest — markets where life-science venture capital has historically been less concentrated than in Boston or the Bay Area.

The firm discloses at least nine exited portfolio companies, all acquired by strategic buyers including Galderma, Exact Sciences (two companies), Supernus, Sunovion, Bionano Genomics, Allergan, Mirum Pharma, Merck, and Nabriva Therapeutics. These exits span dermatology, diagnostics, CNS, genomics, and anti-infectives.

Mesa Verde describes itself as an early-stage venture capital firm that invests directly in seed- and start-up-stage life-science companies. Its public materials do not specify whether it makes fund commitments, GP stakes, or secondary investments.